Sequenom has developed four cancer gene panels: three rather general panels ("OncoCarta" v1.0; v2.0; v3.0), and one specific melanoma panel ("MelaCarta" v1.0). For example, the OncoCarta v1.0 Panel is based on 238 oncogene mutations across 19 common oncogenes (e.g. EGFR, ERBB2, BRAF; for a complete list of genes and mutations, please click here). OncoCarta Panels v2.0 and 3.0 test for an additional 152 and 218 mutations, resp. The MelaCarta v1.0 Panel screens for 72 mutations in 20 genes known to be involved in pathogenesis of melanoma.
Tumor samples from fresh, frozen or formalin-fixed paraffin embedded (FFPE) tissue can be used. Only non-synonymous coding mutations previously reported to occur as somatic mutations in human cancers were selected for the OncoCarta™ Panels. The main advantages of these genetic testing panels are:
- High sensitivity: mutations occuring at less than 10% frequency can be detected and reliably quantitated.
- DNA from FFPE tissue works well.
- Only 500 nanograms of genomic DNA are required per sample.